ABOUT
Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors. Our goal is to save cancer patients’ lives through the development and commercialization of breakthrough therapies that harness the immune system.
Learn More
TECHNOLOGY
Amunix has designed the XPAT platform using its longstanding and validated XTEN technology as a mask for T cell engagers (TCEs). When combined with our proprietary protease release sites, we can selectively unleash the potent activity of TCEs in the tumor by taking advantage of the high protease activity in the tumor microenvironment.
Learn More